Equillium
Edit info- Founded: 2017
- Location: La Jolla, CA
- Employee range: 11 - 50
- Clinical stage: Clin3 (fast track)
- Therapy area: GvHD (ODD)
- Drug types: IMM, X_X, NPH, DRM, GI
- Lead product: EQ001 (partners: Omo Pharmaceuticals, Biocon)
- Funding: $30M stock Feb 2021; $35M stock Aug 2020; $65M IPO
equilliumbio.comhome/default.aspx linkedin.com job board
Business:
Monoclonal Antibody Therapies
Drug notes:
Also Clin1b (Fast track) SLE/lupus nephritis; EQ101 Clin2 alopecia (ODD); EQ102 Clin1 celiac disease; undisclosed RD/Clin0 immunology & inflammatory disorders
About:
Equillium is using advances in immunobiology to create therapeutics to treat autoimmune diseases. A healthy immune system needs to be correctly balanced to ensure it is activated only against pathogenic or cancerous cells. To find effective therapeutics to restore balance, Equillium is using their multi-cytokine inhibitor platform to find peptides that use a novel modality to selectively inhibit multiple disease-driving cytokines, while leaving other immune regulatory pathways intact. Equillium’s lead candidate, Itolizumab, is an immune-modifying monoclonal antibody that downregulates pathogenic T effector cells and is being evaluated for multiple severe immune-inflammatory diseases.
Jobs:
News:
Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease - Yahoo Finance
googlenews
Aug 6, 2024
Science/business updates
external-link
Equillium cancels Metacrine buy, citing 'strong financial position' after Ono deal - Fierce Biotech
googlenews
Dec 27, 2022
Funding-related
external-link
Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease - Business Wire
googlenews
Nov 2, 2022
Science/business updates
external-link
Equillium Provides Timing Update on Conference Presentations - Business Wire
googlenews
Feb 15, 2022
Science/business updates
external-link
Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata - Yahoo Finance
googlenews
Jun 4, 2024
Science/business updates
external-link
Equillium faces delisting risk, Nasdaq warns on bid price
crunchbase
Jul 25, 2024
Science/business updates
external-link
Equillium is no longer buying Metacrine, citing new cash
fiercebiotech.com
Dec 27, 2024
Funding-related
external-link
Equillium to be included in the Russell Microcap® Index
crunchbase
Jun 10, 2024
Funding-related
external-link
Positive Clinical Trial News: Janssen, Humanigen, Pfizer, Equillium and ChemoCentryx - BioSpace
googlenews
Nov 6, 2020
Science/business updates
external-link
Equillium’s Q3 Financials and Clinical Progress in Focus - TipRanks
googlenews
Nov 13, 2024
Science/business updates
external-link
Equillium Maintains Rights to Itolizumab Following Ono Partnership - Yahoo Finance
googlenews
Oct 31, 2024
Science/business updates
external-link
SGIOY: 3 Biotech Stocks Under $20 Worth Watching in June - StockNews.com
googlenews
May 31, 2024
Science/business updates
external-link
Single-asset Equillium buys Bioniz for up to $329M, adding ...
fiercebiotech.com
Dec 27, 2024
Funding-related
external-link
Week of 10/30 Fed balance sheet reserve bank credit $18,205B
crunchbase
Oct 31, 2024
Science/business updates
external-link
EQ101 demonstrates favorable efficacy, tolerability for treatment of alopecia areata - Healio
googlenews
Jun 5, 2024
Science/business updates
external-link
Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata
crunchbase
Jun 4, 2024
Science/business updates
external-link
Equillium reports favorable Phase 2 results for alopecia treatment By Investing.com
crunchbase
Jun 3, 2024
Science/business updates
external-link
Equillium delivers new lupus data to Ono's doorstep
crunchbase
Apr 17, 2024
Science/business updates
external-link
Equillium CEO, Bruce Steel, presenting today at 4:30 pm ET at the 2024 Wells Fargo Healthcare Conference in Boston.
Presentation will provide an overview of the EQ's multi-cytokine inhibitor program
linkedin
Sep 27, 2024
Science/business updates
external-link
Maker of transplant rejection drug Equillium sees shares rise after successful trial - Kursiv Media
googlenews
Aug 7, 2024
Science/business updates
external-link
Week of 10/30 Fed balance sheet level $7.013T
crunchbase
Oct 31, 2024
Science/business updates
external-link
Cutaneous T-Cell Lymphoma Market to Evolve Rapidly from 2024 to 2034 | DelveInsight | Angimmun, Philogen, Soligenix
crunchbase
Dec 17, 2024
Science/business updates
external-link
It's conference season again!
Equillium, Inc. presenting tomorrow, Tuesday, September 10th at 8:00 am ET at the H.C. Wainwright & Co., LLC Investor Conference. CEO, Bruce Steel, will provide an up
linkedin
Sep 27, 2024
Science/business updates
external-link
Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
crunchbase
Nov 8, 2023
Science/business updates
external-link
Equillium stock touches 52-week low at $0.6 amid market challenges - Investing.com
googlenews
Dec 19, 2024
Science/business updates
external-link
Equillium swaps multi-cytokine inhibitor for oral option after ...
fiercebiotech.com
Dec 27, 2024
Science/business updates
external-link
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro ...
crunchbase
Mar 22, 2024
Science/business updates
external-link
Single-asset Equillium buys Bioniz for up to $329M, adding 3 drugs to its pipeline - Fierce Biotech
googlenews
Feb 16, 2022
Funding-related
external-link
Clinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with COVID-19 - GlobeNewswire
googlenews
Jul 13, 2020
Science/business updates
external-link
Even after rising 85% this past week, Equillium (NASDAQ:EQ) shareholders are still down 85% over the past three years
crunchbase
Feb 10, 2024
Science/business updates
external-link
Equillium to Present at the SVB Securities Annual Global Healthcare Conference
crunchbase
Feb 7, 2023
Science/business updates
external-link
As we enter the weekend, we want to welcome our newest team member, Hareth Yousef. Hareth joins the Clinical Operations Team as a Clinical Trial Associate. He will be supporting the EQUATOR program
linkedin
Jun 27, 2024
New hires
external-link
Equillium to Participate in Upcoming Investor Conferences
crunchbase
Jul 2, 2024
Funding-related
external-link
Equillium Maintains Rights to Itolizumab Following Ono Partnership - StockTitan
googlenews
Oct 31, 2024
Science/business updates
external-link
Walk For Alopecia™ - National Alopecia Areata Foundation | NAAF
linkedin
Sep 27, 2024
Science/business updates
external-link
Equillium keeps equilibrium in GVHD after Ono no-go
crunchbase
Oct 31, 2024
Science/business updates
external-link
Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer - Business Wire
googlenews
Oct 7, 2024
Science/business updates
external-link
Equillium announces data from EQ101 study
crunchbase
Jun 4, 2024
Science/business updates
external-link
Equillium to Present at the Jefferies Global Healthcare Conference
crunchbase
May 29, 2024
Science/business updates
external-link
Equillium to Present at the JonesTrading 2023 Healthcare Summit
crunchbase
Oct 2, 2023
Science/business updates
external-link
Equillium's lupus drug improves kidney biomarker, teeing up opt-in decision from Ono - Fierce Biotech
googlenews
Apr 1, 2024
Science/business updates
external-link
Equillium swaps multi-cytokine inhibitor for oral option after underwhelming phase 2 data - Fierce Biotech
googlenews
Dec 21, 2023
Science/business updates
external-link
Acquisitive Roche, Equillium Sink Funds into IL-2 and GI Drugs - BioSpace
googlenews
Sep 7, 2022
Funding-related
external-link
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates
crunchbase
Nov 13, 2024
Science/business updates
external-link
Equillium posts early mid-stage data for hair loss therapy
crunchbase
Jun 4, 2024
Science/business updates
external-link
Equillium Sees Positive Data From Phase 2 Study of EQ101
crunchbase
Jun 3, 2024
Science/business updates
external-link
Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates
crunchbase
Apr 17, 2024
Science/business updates
external-link
Equillium reports inducement grant under Nasdaq listing rule
crunchbase
Apr 3, 2024
Funding-related
external-link
Individual investors account for 41% of Equillium, Inc.'s (NASDAQ:EQ) ownership, while insiders account for 20%
crunchbase
Mar 22, 2024
Funding-related
external-link
Equillium and Biocon Announce Positive COVID-19 Data for Plaque Psoriasis Drug Itolizumab - BioSpace
googlenews
Jul 13, 2020
Science/business updates
external-link
Equillium Announces Pricing of Initial Public Offering - GlobeNewswire
googlenews
Oct 12, 2018
Funding-related
external-link
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in ...
crunchbase
Apr 2, 2024
Science/business updates
external-link
Equillium Inc reports results for the quarter ended in March - Earnings Summary
crunchbase
May 9, 2024
Science/business updates
external-link
Today we announced that an abstract was accepted for poster presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
Title: Interleukin (IL)-15 and IL-21 synergisti
linkedin
Oct 27, 2024
Science/business updates
external-link
Equillium Announces $7.5 Million Share Repurchase Program
crunchbase
Aug 2, 2023
Funding-related
external-link
Equillium retains rights to itolizumab after Ono's option expires - Investing.com
googlenews
Oct 31, 2024
Science/business updates
external-link
News wrap: Equillium axes Metacrine merger; Two pharmas pen ADC deals
crunchbase
Dec 29, 2022
Science/business updates
external-link
Itolizumab - world’s first novel anti-CD6 monoclonal antibody in India - Biocon
googlenews
Sep 5, 2020
Science/business updates
external-link
Equillium buys struggling Metacrine in $26M all-stock deal
fiercebiotech.com
Dec 27, 2024
Funding-related
external-link
Biocon's partner Equillium plans Itolizumab's global clinical trial for COVID-19 - Moneycontrol
googlenews
Jul 13, 2020
Science/business updates
external-link
"At Equillium, our community matters!" Thank you Life Science Cares San Diego and Feeding San Diego for your partnership!
#LifeScienceCaresSanDiego #FeedingSanDiego #CommunityDay #SocialResponsibil
linkedin
Jul 27, 2024
Science/business updates
external-link
Biotech firm Equillium loses third of market value in a day after Ono no-go - Kursiv Media
googlenews
Nov 1, 2024
Science/business updates
external-link
Equillium shares downgraded to hold from buy - Investing.com
googlenews
Oct 31, 2024
Science/business updates
external-link
Equillium says Ono not acquiring itolizumab, stock craters 36%
crunchbase
Oct 31, 2024
Science/business updates
external-link
Equillium to Participate in Upcoming Investor Conferences - Business Wire
googlenews
Jul 2, 2024
Funding-related
external-link
Ono Pharma buys rights to Equillium’s itolizumab - The Pharma Letter
googlenews
Dec 6, 2022
Funding-related
external-link
Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance - Business Wire
googlenews
Jul 18, 2024
Funding-related
external-link
Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
crunchbase
Oct 31, 2024
Science/business updates
external-link
Equillium just downgraded at JonesResearch, here's why
crunchbase
Oct 31, 2024
Science/business updates
external-link
Equillium Announces Three Poster Presentations at the Annual Meeting of The American Association of Immunologists - Business Wire
googlenews
May 9, 2022
Science/business updates
external-link
Equillium sees $26M Metacrine buy as opportunity to boost its balance sheet - Fierce Biotech
googlenews
Sep 7, 2022
Funding-related
external-link
Equillium Announces Board and Audit Committee Changes - TipRanks
googlenews
Dec 12, 2024
New hires
external-link
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102
crunchbase
Dec 21, 2023
Science/business updates
external-link
Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit - Business Wire
googlenews
Sep 10, 2024
Science/business updates
external-link
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
crunchbase
Sep 4, 2024
Funding-related
external-link
Equillium to advance EQ-302 in place of EQ-102 for gastrointestinal and skin diseases - BioWorld Online
googlenews
Dec 22, 2023
Science/business updates
external-link
Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer - Business Wire
googlenews
Nov 12, 2024
Science/business updates
external-link
Equillium Reveals Breakthrough Immune Response Data at Major Cancer Conference - StockTitan
googlenews
Nov 12, 2024
Science/business updates
external-link
Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus ...
crunchbase
May 14, 2024
Science/business updates
external-link
Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates
crunchbase
May 10, 2024
Science/business updates
external-link
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
crunchbase
May 15, 2023
Science/business updates
external-link
Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth - Yahoo Finance
googlenews
Nov 6, 2024
Science/business updates
external-link
Equillium (NASDAQ:EQ) adds US$25m to market cap in the past 7 days, though investors from three years ago are still down 85%
crunchbase
Feb 10, 2024
Science/business updates
external-link
Restoring immune balance: Targeting CD6 to treat autoimmune and inflammatory disease - Nature.com
googlenews
Dec 26, 2020
Science/business updates
external-link
Equillium to Present at the Stifel Healthcare Conference - Business Wire
googlenews
Nov 13, 2024
Science/business updates
external-link
Graft-Versus-Host Disease Market on Track for Major Expansion by 2034, According to DelveInsight | CSL Behring, Equillium, Biocon, MaaT Pharma, Regimmune, Jazz Pharma, Pharmacyclics, Novartis - The Gl
googlenews
Dec 17, 2024
Science/business updates
external-link
Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit
crunchbase
Sep 10, 2024
Science/business updates
external-link
Equillium to Acquire Metacrine in All-Stock Transaction - Business Wire
googlenews
Sep 6, 2022
Funding-related
external-link
Equillium keeps equilibrium in GVHD after Ono no-go - BioWorld Online
googlenews
Oct 31, 2024
Science/business updates
external-link
Equillium’s itolizumab shows promise in phase 3 graft versus host disease study - PMLiVE
googlenews
Aug 12, 2024
Science/business updates
external-link
Equillium Maintains Rights to Itolizumab Following Ono Partnership
crunchbase
Oct 31, 2024
Science/business updates
external-link
Equillium says Ono not acquiring itolizumab, stock craters 36% (NASDAQ:EQ) - Seeking Alpha
googlenews
Oct 31, 2024
Science/business updates
external-link
Week of 10/30 Fed balance sheet total assets $15,918B
crunchbase
Oct 31, 2024
Science/business updates
external-link
From our humble table to yours, happy Thanksgiving.
linkedin
Nov 27, 2024
None of the above (Note: This title does not fit into any of the provided categories, as it appears to be a holiday greeting rather than a news article about funding, new hires, or science/business updates)
external-link
© 2025 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com